Trial · NCT00118248
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin) | Advanced Medullary Thyroid Carcinoma Group | 5.9 | 90% Confidence Interval 0.3 to 25.0 | percentage of participants | |
| Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin) | Differentiated Thyroid Carcinoma | 12.5 | 90% Confidence Interval 3.5 to 29.2 | percentage of participants | |
| Overall Response | Advanced Medullary Thyroid Carcinoma Group | Complete Response (CR) | 0 | participants | |
| Overall Response | Differentiated Thyroid Carcinoma | Complete Response (CR) | 0 | participants | |
| Overall Response | Advanced Medullary Thyroid Carcinoma Group | Partial Response (PR) | 1 | participants | |
| Overall Response | Differentiated Thyroid Carcinoma | Partial Response (PR) | 0 | participants | |
| Progression-Free Survival | Advanced Medullary Thyroid Carcinoma Group | 6.4 | 95% Confidence Interval 2.7 to 17.2 | months | |
| Progression-Free Survival | Differentiated Thyroid Carcinoma | 4.1 | 95% Confidence Interval 2.2 to 8.7 | months | |
| Overall Survival | Advanced Medullary Thyroid Carcinoma Group | 2.1 | 95% Confidence Interval 0.67 to 3.1 | years | |
| Overall Survival | Differentiated Thyroid Carcinoma | 1.5 | 95% Confidence Interval 0.73 to 3.5 | years | |
| Toxicity | Advanced Medullary Thyroid Carcinoma Group | Grade 3 or Higher | 4 | participants | |
| Toxicity | Differentiated Thyroid Carcinoma | Grade 3 or Higher | 9 | participants | |
| Toxicity | Advanced Medullary Thyroid Carcinoma Group | Grade 4 or Higher | 3 | participants | |
| Toxicity | Differentiated Thyroid Carcinoma | Grade 4 or Higher | 0 | participants | |
| Toxicity | Advanced Medullary Thyroid Carcinoma Group | Grade 5 | 1 | participants | |
| Toxicity | Differentiated Thyroid Carcinoma | Grade 5 | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00118248/results